Skip to main content

Table 1 Virus strain composition and antigenic content of each annual influenza vaccine

From: Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial

Vaccine dosage and route* Strain composition
Year 1: Northern Hemisphere 2003–2004 formulation:
3 μg ID or A/New Caledonia/20/99 (H1N1) (A/New Caledonia/20/99-like strain)
6 μg ID or A/Panama/2007/99 (H3N2) (A/Moscow/10/99-like strain)
15 μg IM B/Shandong/7/97 (B/Hong Kong/330/2001-like strain)
Year 2: Northern Hemisphere 2004–2005 formulation:
9 μg ID or A/New Caledonia/20/99 (H1N1) (A/New Caledonia/20/99-like strain)
15 μg IM A/Wyoming/3/2003 (H3N2) (A/Fujian/411/2002-like strain)
B/Jiangsu/10/2003 (B/Shanghai/361/2002-like strain)
Year 3: Southern Hemisphere 2005 formulation:
9 μg ID, or A/New Caledonia/20/99 IVR-116 (H1N1) (A/New Caledonia/20/99-like strain)
15 μg IM A/Wellington/1/2004 IVR-139 (H3N2) (A/Wellington/1/2004-like strain)
B/Jiangsu/10/2003 (B/Shanghai/361/2002-like strain)
  1. *Intradermal (ID) vaccines were formulated to contain 3, 6, 9 μg of haemagglutinin (HA) per strain in a volume of 0.1 ml and administered by microinjection; the intramuscular (IM) vaccine was the licensed vaccine Vaxigrip®, containing 15 μg of (HA) per strain in a volume of 0.5 ml.